{"filing":{"accession_number":"0001731122-26-001152","cik":"0001553788","ticker":"SBEVW","company_name":"Endovia Health Sciences, Inc.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-20","primary_document":"e7899_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001152/e7899_8-k.htm"},"events":[{"id":29794,"run_id":27291,"accession_number":"0001731122-26-001152","anchor_item_number":"1.01","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses employment agreements with Brady Cobb (Interim CEO) and Michael Bondurant (Interim COO) that center on compensatory arrangements: base salaries ($300,000 and $275,000), performance-based cash bonuses tied to market capitalization milestones, option grants (231,250 and 200,000 respectively), and conditional RSU grants. While the agreements also formalize their executive appointments, the substantive disclosure focuses on the compensation structure and equity incentives, making this primarily a compensation event rather than a pure appointment.","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":32181,"accession_number":"0001731122-26-001152","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses employment agreements with Brady Cobb (Interim CEO) and Michael Bondurant (Interim COO) that center on compensatory arrangements: base salaries ($300,000 and $275,000), performance-based cash bonuses tied to market capitalization milestones, option grants (231,250 and 200,000 respectively), and conditional RSU grants. While the agreements also formalize their executive appointments, the substantive disclosure focuses on the compensation structure and equity incentives, making this primarily a compensation event rather than a pure appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:35:49.215007+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32181,"accession_number":"0001731122-26-001152","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses employment agreements with Brady Cobb (Interim CEO) and Michael Bondurant (Interim COO) that center on compensatory arrangements: base salaries ($300,000 and $275,000), performance-based cash bonuses tied to market capitalization milestones, option grants (231,250 and 200,000 respectively), and conditional RSU grants. While the agreements also formalize their executive appointments, the substantive disclosure focuses on the compensation structure and equity incentives, making this primarily a compensation event rather than a pure appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:35:49.215007+00:00","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-08-26"}]}